Alys Pharmaceuticals conducts research and development focused on immuno‑dermatology, creating targeted therapies for dermatologic immune disorders. Its pipeline includes multi‑platform programs such as ALY‑301, a mast cell‑selective c‑Kit inhibitor currently in Phase 1/1b trials for chronic urticaria, aiming to address unmet patient needs. The company monetizes its products through commercial drug sales and licensing agreements upon regulatory approval.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many dermatological conditions lack effective treatments, leaving patients with unmet medical needs. Current solutions may not adequately address the underlying immune-related mechanisms of these skin disorders. This results in persistent symptoms and reduced quality of life for affected individuals.
Solution
Alys Pharmaceuticals is developing a pipeline of immuno-dermatology treatments using multi-platform technologies. By targeting the immune system's role in skin disorders, Alys aims to create transformative solutions for a range of dermatological conditions. Their research and development efforts focus on addressing unmet needs and improving patient outcomes in the field of immuno-dermatology.
Target Audience
The primary target audience includes patients suffering from skin-related immune disorders with unmet medical needs, as well as the dermatologists and healthcare providers who treat them.
Features
- R&D pipeline focused on immuno-dermatology.
- Utilizes multi-platform technologies to target various dermatological conditions.
- Pipeline includes over a dozen active programs.
- Focus on innovative programs and platforms.